Tacrolimus treatment increases bone formation in patients with rheumatoid arthritis

Rheumatology International

Volumn 33, Issue 8, 2013, Pages 2159-2163

  Kang, Kwi Young ^a   Ju, Ji Hyeon ^b   Song, Yeong Wook ^c   Yoo, Dae Hyun ^d   Kim, Ho Youn ^b   Park, Sung Hwan ^b  

^a Chungbuk National University Hospital   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Seoul National University   (South Korea)

^d Hanyang University College of Medicine   (South Korea)

Author keywords

Calcineurin; NFAT; Osteoblast; Osteocalcin; Tacrolimus

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; OSTEOCALCIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BONE METABOLISM; CLINICAL ARTICLE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; OSSIFICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; INTERLEUKIN-6; MALE; MIDDLE AGED; OSTEOCALCIN; OSTEOGENESIS; TACROLIMUS;

EID: 84880918198     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2370-z     Document Type: Article

References (15)

1. Panayi GS, Lanchbury JS, Kingsley GH (1992) The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 35:729-735
2. Dumont FJ (2000) FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem 7:731-748
3. Sitara D, Aliprantis AO (2010) Transcriptional regulation of bone and joint remodeling by NFAT. Immunol Rev 233:286-300
4. Ranger AM, Oukka M, Rengarajan J, Glimcher LH (1998) Inhibitory function of two NFAT family members in lymphoid homeostasis and Th2 development. Immunity 9:627-635
5. Takayanagi H (2005) Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 83:170-179
6. Miyazaki M, Fujikawa Y, Takita C, Tsumura H (2007) Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis. Clin Rheumatol 26:231-239
7. Yoshikawa T, Nakajima H, Uemura T, Kasai T, Enomoto Y, Tamura T et al (2005) In vitro bone formation induced by immunosuppressive agent tacrolimus hydrate (FK506). Tissue Eng 11:609-617
8. Koga T, Matsui Y, Asagiri M, Kodama T, de Crombrugghe B, Nakashima K et al (2005) NFAT and Osterix cooperatively regulate bone formation. Nat Med 11:880-885
9. Spolidorio LC, Nassar PO, Nassar CA, Spolidorio DM, Muscara MN (2007) Conversion of immunosuppressive monotherapy from cyclosporin a to tacrolimus reverses bone loss in rats. Calcif Tissue Int 81:114-123
10. Yeo H, Beck LH, Thompson SR, Farach-Carson MC, McDonald JM, Clemens TL et al (2007) Conditional disruption of calcineurin B1 in osteoblasts increases bone formation and reduces bone resorption. J Biol Chem 282:35318-35327
11. Sun L, Blair HC, Peng Y, Zaidi N, Adebanjo OA, Wu XB et al (2005) Calcineurin regulates bone formation by the osteoblast. Proc Natl Acad Sci USA 102:17130-17135
12. Cvetkovic M, Mann GN, Romero DF, Liang XG, Ma Y, Jee WS et al (1994) The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 57:1231-1237
13. Yeo H, Beck LH, McDonald JM, Zayzafoon M (2007) Cyclosporin A elicits dose-dependent biphasic effects on osteoblast differentiation and bone formation. Bone 40:1502-1516
14. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E et al (2000) Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43:250-258
15. Magari K, Nishigaki F, Sasakawa T, Ogawa T, Miyata S, Ohkubo Y et al (2003) Anti-arthritic properties of FK506 on collagen-induced arthritis in rats. Inflamm Res 52:524-529